1,340
Views
27
CrossRef citations to date
0
Altmetric
Pharmacotherapy

Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma

, MD, , MPH, , PhD, MPH, , MD, , MD, MS, , III, MD, , MD, , MD & , PhD, MPH show all
Pages 194-200 | Received 11 Mar 2015, Accepted 08 Jul 2015, Published online: 17 Sep 2015

References

  • CDC. Asthma. 2013. Available from: http://www.Cdc.Gov/asthma/ [last accessed 5 Aug 2014]
  • Nih. Asthma info. 2013. Available from: http://www.Nhlbi.Nih.Gov/health-pro/resources/lung/naci/asthma-info/ [last aaccessed 4 Aug 2014]
  • Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004;24:659–663
  • Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, et al., Group AIRTS. Asthma control during the year after bronchial thermoplasty. New Engl J Med 2007;356:1327–1337
  • Torrego A, Sola I, Munoz AM, Roque IFM, Yepes-Nunez JJ, Alonso-Coello P, Plaza V. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev 2014;3:CD009910
  • Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, Chung KF, Laviolette M, Group RTS. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007;176:1185–1191
  • Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, et al., Group AIRTS. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181:116–124
  • Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, et al., Asthma Intervention Research 2 Trial Study G. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132:1295–1302
  • Cangelosi MJ, Ortendahl JD, Meckley LM, Bentley TG, Anene AM, Shriner KM, Fox J. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Expert Rev Pharmacoeconom Outcomes Res 2015;15:357–364
  • Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996;276:1339–1341
  • Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253–1258
  • Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, Krishnan JA. Mortality in patients hospitalized for asthma exacerbations in the united states. Am J Respir Crit Care Med 2006;174:633–638
  • Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76–83
  • The Healthcare Cost and Utilization Project (HCUP). Available from: http://www.hcup-us.ahrq.gov [last accessed 12 Jul 2014]
  • MM7443 – Centers for Medicare & Medicaid Services; July 1 AfhwcgO-a-EM-L-N-MMdmp
  • The Consumer Price Index program – Bureau of Labor Statistics. Available from: http://www.bls.gov/cpi/ [last accessed 12 Jul]
  • Center for the Evaluation of Value and Risk in Health. The cost-effectiveness analysis registry. Boston: Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Available from: www.cearegistry.org [last accessed 5 Jul 2014]
  • Allegra L, Cremonesi G, Girbino G, Ingrassia E, Marsico S, Nicolini G, Terzano C, Group PS. Real-life prospective study on asthma control in italy: cross-sectional phase results. Respir Med 2012;106:205–214
  • Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, Bateman ED, Group GI. Cost-effectiveness of asthma control: an economic appraisal of the goal study. Allergy 2006;61:531–536
  • Steuten L, Palmer S, Vrijhoef B, van Merode F, Spreeuwenberg C, Severens H. Cost-utility of a disease management program for patients with asthma. Int J Technol Assess Health Care 2007;23:184–191
  • Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65:1141–1148
  • Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Resp J 2004;13:113–4
  • Tsuchiya A BJ, McColl E, Parkin D. Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices. 2002. Available from: http://eprints.whiterose.ac.uk/10952/1/HEDS_DP_02-01.pdf [last accessed 15 Jul 2014]
  • CDC – Division of Vital Statistics – National Center for Health Statistics. Available from: http://www.cdc.gov/nchs/nvss/mortality_tables.htm [last accessed on 15 Jul 2014]
  • Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness – the curious resilience of the $50,000-per-qaly threshold. New Engl J Med 2014;371:796–797
  • Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the united states: evidence from the medical expenditure panel survey. J Allergy Clin Immunol 2011;127:363–369, e361–363
  • World Health Organization– Cost-effectiveness threaholds. Available from: http://www.who.int/choice/costs/CER_thresholds/en/ [last accessed 19 Jul 2014]
  • Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108:39–46
  • Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmaco Economics 2007;25:577–590
  • Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997;156:787–793
  • Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med 1999;160:211–215
  • Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the united states. New Engl J Med 1992;326:862–866
  • Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J Allergy Clin Immunol 2007;120:1146–1152
  • Barrett ML, Wier LM, WashingtonR. Healthcare Cost and Utilization Project (HCUP); trends in pediatric and adult hospital stays for asthma, 2000–2010. January 2014. Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb169-Asthma-Trends-Hospital-Stays.jsp [last accessed 12 Aug 2014]
  • Merrill CT, Stranges E, Steiner C. Hospital stays related to asthma for adults, 2005: statistical brief #54. Healthcare cost and utilization project (hcup) statistical briefs. Rockville (MD); 2006
  • O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. PharmacoEconomics 2004;22:815–825

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.